EPISODE · Jun 21, 2023 · 16 MIN
Inducing Potent and Durable T Cell Responses to Fight Disease
from The Bio Report · host Levine Media Group
Vaccitech first gained attention as co-inventor of the Covid-19 vaccine licensed to AstraZeneca. The University of Oxford spin-out is developing a pipeline of T cell immunotherapies to treat and cure chronic infectious diseases, autoimmune diseases, and cancers. The company’s lead experimental therapy is a potentially curative monotherapy for chronic hepatitis B viral infection. We spoke to Bill Enright, CEO of Vaccitech, about the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.
What this episode covers
Bill Enright, CEO of Vaccitech, discusses the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.
NOW PLAYING
Inducing Potent and Durable T Cell Responses to Fight Disease
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m